Heavy-chain immunoglobulin locus editing in rhesus macaque B cells to confer antibody production.

ABSTRACT: Antibody-based immunotherapies are promising; however, their application remains limited to acute diseases due to rapid clearance of antibodies in vivo. Some chronic conditions could benefit from sustained therapeutic antibody expression. One such instance is human immunodeficiency virus type 1 (HIV-1), where the efficiency of broadly neutralizing antibodies by passive immunization has been limited in clinical trials. B cell editing to enable sustained production of an antibody of interest in vivo could address this issue. However, the long-term potential of this approach and feasibility to perform editing in B cells from people living with HIV remain to be determined. We investigated editing of rhesus macaque B cells from healthy or simian/human immunodeficiency virus (SHIV)

SUBMITTER: Kuhlmann AS 

PROVIDER: S-EPMC12554106 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature